JUL 19, 2016 7:51 AM PDT

CAR-T Cells that Kill Cancer Now Kill HIV Too

WRITTEN BY: Xuan Pham
A decade-old technology to arm the immune system to fight cancer is now being adapted to fight HIV, one of the most pernicious viruses in human history. The premise of this immunotherapy rests on chimeric antigen receptor (CAR) T cells that are now mobilized to destroy HIV.

Technique to boost immune system to fight cancer can also fight HIV | Image: NIAID/Flickr
 
Immunotherapy is a relatively new and attractive line of treatment that stimulates the body’s natural defenses to kill foreign invader cells. Most prominently, this technology has been successfully adapted to target and destroy some cancer types.
 
In particular, one type of cancer immunotherapy involves the genetically modification of the patient’s immune T-cells to carry a synthetic receptor molecule called a CAR (for chimeric antigen receptor). These specialized CAR-T cells are then able to recognize and destroy cancer cells that have a specific marker, known as CD19.
 
Because CAR-T cells have been effective at boosting the patient’s own immune system to fight cancer, researchers have wondered whether this technology can be adapted to fight HIV. Indeed, such experiments were carried out in the early 1990s, but were soon halted due to the lack of effectiveness in clinical trials. However, the promise of CAR-T immunotherapy prevailed, and prompted a fresh start by scientists at the UCLA AIDS Institute and Center for AIDS Research.
 
Fortunately this time, CAR-T cells appear to be a new powerful weapon against HIV. The secret to their success? UCLA researchers had access to new antibodies that were only discovered in the past few years.
 
Specifically, the team had seven antibodies that were classified as “broadly neutralizing antibodies,” meaning these proteins can bind to many types of viruses. Then, researchers exploited this capability by making CAR-T cells with receptors against a number of HIV strains.
 

 "We took new generation antibodies and engineered them as artificial T-cell receptors, to reprogram killer T cells to kill HIV-infected cells," said Otto Yang, a professor at the School of Medicine at UCLA, and director of vaccine and pathogenesis research at the AIDS Institute and Center for AIDS Research. "Others have used antibodies against cancer antigens to make artificial T-cell receptors against cancer and shown this to be helpful in cancer treatment."
 
In the lab, this translated to killer T cells that can multiply, and then target HIV-infected cells for destruction. And while the immune system can do this naturally, the onslaught of HIV infection overwhelms the body’s responses. Having CAR-T cells would boost this reaction, such that the immune system can overcome HIV.
 
While this is the first success of immunotherapy against HIV in 15 years, the research team is proceeding cautiously. "What works in a test tube doesn't necessarily work in a person, so the next step is to find strategies to put these receptors into humans. But this therapy shows enough promise to move forward with further research," said Yang.

Additional sources: UCLA press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 15, 2020
Cancer
MAR 15, 2020
The racism behind cancer
Researchers from the University of Colorado Cancer Center have made strides in understanding the reasons behind disparit ...
APR 19, 2020
Cancer
APR 19, 2020
Discovery of new biomarker detects urological cancer
New hope for the detection of urological cancers has been published in a study in the Journal of Extracellular Vesicles. ...
APR 21, 2020
Cancer
APR 21, 2020
Scientists develop tumor immunity map
A new study published in eLife describes the findings from a study that has successfully mapped tumor cell molecule ...
APR 27, 2020
Cancer
APR 27, 2020
Talazoparib offers improved quality of life for breast cancer patients
Findings from the Phase III EMBRACA trial have been reported at the American Association for Cancer Research (AACR) annu ...
MAY 21, 2020
Cancer
MAY 21, 2020
When is the best time to talk about end-of-life decisions with your teen who has cancer?
A study published recently in JAMA Network highlights the need for improved pediatric advanced care for adolescents with ...
MAY 10, 2020
Drug Discovery & Development
MAY 10, 2020
Antiviral Drug Treats Naso-Pharyngeal Cancer
Scientists at Hong Kong Baptist University (HKBU) developed a novel anti-Epstein-Barr virus (EBV) drug that can shrink t ...
Loading Comments...